Survival Outcomes of Patients Treated with Hypofractionated Stereotactic Body Radiation Therapy for Parotid Gland Tumors: a Retrospective Analysis

Abstract

Background: to review a single-institution experience with the management of parotid malignancies treated by fractionated stereotactic body radiosurgery (SBRT). Findings: Between 2003 and 2011, 13 patients diagnosed with parotid malignancies were treated with adjuvant or definitive SBRT to a median dose of 33 Gy (range 25–40 Gy). There were 11 male and two female patients with a median age of 80. Ten patients declined conventional radiation treatment and three patients had received prior unrelated radiation therapy to neighboring structures with unavailable radiation records. Six patients were treated with definitive intent while seven patients were treated adjuvantly for adverse surgical or pathologic features. Five patients had clinical or pathologic evidence of lymph node disease. Conclusion: at a median follow-up of 14 months only one patient failed locally, and four failed distantly. The actuarial 2-year overall survival, progression-free survival, and local-regional control rates were 46, 84, and 47%, respectively. Statistical analysis revealed surgery as a positive predictor of overall survival while presence of gross disease was a negatively correlated factor (p < 0.05).

Parotid metastasis from carcinoma urinary bladder treated with CyberKnife-based stereotactic body radiotherapy: case report and review of literature

“…The CyberKnife SBRT system uses real-time image guidance for targeting without rigid external fixation. SBRT for the primary (definitive or adjuvant) treatment and re-irradiation of recurrent primary parotid tumours has been reported by Karam et al 14,15 With a median follow-up of 14 months, local control rate of 92% and an actuarial rate of 84% at 2 years has been reported. We were unable to find studies of SBRT for parotid metastasis.…”

Stereotactic Radiation Therapy for De Novo Head and Neck Cancers: A Systematic Review and Meta-Analysis

“…A total of 9 studies (2 prospective, 7 retrospective) were identified for inclusion, representing 157 mutually exclusive patients. 9 , 10 , 15 , 25 , 26 , 27 , 28 , 29 , 30 Individual study characteristics are summarized in Table 2 . The 2 prospective larynx studies were included despite some patients receiving more than 10 fractions.…”

“…The pooled median patient age across studies was approximately 76 years. The 2 prospective studies were of larynx cancers, 25 , 29 with remaining retrospective studies parotid (n = 1) 26 and mixed (n = 6) subsites.…”

Stereotactic Body Radiotherapy as Primary Therapy for Head and Neck Cancer in the Elderly or Patients with Poor Performance

“…Toxicities were mostly grade 1 or 2 with one grade 3 osteonecrosis in a patient who received a second treatment of SBRT following disease recurrence. Similarly, in another retrospective analysis of elderly patients treated with primary SBRT for salivary gland tumors, Karam et al showed 2-year local control rate of 84% at a median follow-up of 14 months ( 24 ). The treatment was also reportedly well tolerated with no grade 4 toxicities.…”